Farrell Tyson, MD
Ophthalmology · Cape Coral, FLNPI 1508857491
Payments from drug & device makers
Across 634 payments — averaging $1395.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec Cataract Technology Inc.$429K
- Alcon$146K
- Glaukos Corporation$85K
- Alcon Research LLC$45K
- Carl Zeiss Meditec Production LLC$39K
- Rxsight Inc$38K
- plus $102K from 23 others
Across 2 payments — averaging $20,819 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Carl Zeiss Meditec Cataract Technology Inc.$38K
- Bausch Health US, LLC$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec Cataract Technology Inc. | 97 | $428,814 |
| Alcon | 145 | $146,444 |
| Glaukos Corporation | 101 | $84,657 |
| Alcon Research LLC | 28 | $45,336 |
| Carl Zeiss Meditec Production LLC | 5 | $39,149 |
| Rxsight Inc | 7 | $37,972 |
| Bausch & Lomb Americas Inc. | 54 | $35,070 |
| Carl Zeiss Meditec, Inc. | 16 | $18,615 |
| AbbVie(2 entities) | 56 | $18,014 |
| Carl Zeiss Meditec USA, Inc. | 10 | $9,997 |
| Carl Zeiss Meditec AG | 1 | $6,000 |
| Bausch Health US, LLC | 3 | $5,728 |
| Sun Pharmaceutical Industries Inc. | 12 | $3,393 |
| Johnson & Johnson Surgical Vision, Inc. | 31 | $1,428 |
| Dutch Ophthalmic Research Center (international) B.v. | 5 | $1,340 |
| Lensar, Inc. | 9 | $667 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $531 |
| Dutch Ophthalmic, USA | 9 | $526 |
| Aerie Pharmaceuticals, Inc. | 4 | $240 |
| Ivantis, Inc | 6 | $217 |
| Harrow Eye, LLC | 2 | $173 |
| Dompe US, Inc. | 3 | $159 |
| Rayner Intraocular Lenses Limited | 4 | $65 |
| Kala Pharmaceuticals, Inc. | 3 | $53 |
| Eyepoint US, Inc. | 1 | $43 |
| Novartis | 1 | $28 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Lombart Brothers, Inc. | 1 | $7 |
How this compares
$884,705 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Cape Coral
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.